LK
Lawrence A Kenyon
Chief Financial OfficerDirector

Lawrence A Kenyon insider trades: Outlook Therapeutics (OTLK) stock buys and sales

Chief Financial Officer, Outlook Therapeutics Last trade Sep 26, 2024 26 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
8
Open-market trades
since 2007
6
Companies
last trade 2024

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Lawrence reports to the SEC

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Sep 26, 2024OTLK↑ Buy$28K
Apr 20, 2021OTLK↑ Buy$18K
Sep 18, 2019OTLK↓ Sell$2K
Feb 7, 2019OTLK↑ Buy$22K
Sep 18, 2018ONS↓ Sell$9K
Dec 22, 2017ONS↓ Sell$30K
Mar 3, 2010PRX↓ Sell$540K
Apr 11, 2007ACEL↑ Buy$53K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other OTLK insiders

Open-market trades in the last 12 months

About Lawrence A Kenyon's insider trades

Lawrence A Kenyon is Chief Financial Officer at Outlook Therapeutics (OTLK). Since Apr 11, 2007, Lawrence has reported 4 open-market purchases worth $123K and 4 sales worth $581K on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (15 filings), shares withheld for taxes (2 filings), other transactions (1 filing), option exercises (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OTLK insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.